Enrolling by invitationNCT07555171
EEG Dynamics in Lennox-Gastaut Syndrome Patients Undergoing Fenfluramine Treatment
Studying Epilepsy syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Chicago
- Intervention
- fenfluramine HCl(drug)
- Enrollment
- 20 target
- Eligibility
- 2-35 years · All sexes
- Timeline
- 2026 – 2028
Study locations (1)
- University of Chicago, Chicago, Illinois, United States
Collaborators
UCB Pharma
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07555171 on ClinicalTrials.govOther trials for Epilepsy syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07531745ASCEND: Safety and Tolerability of ION337 for the Treatment of Dravet SyndromeIonis Pharmaceuticals, Inc.
- RECRUITINGPHASE3NCT07234695LEvetiracetam to Prevent Seizures in Symptomatic Alzheimer's Disease in Adults With Down SyndromeFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
- RECRUITINGNCT06967727Registry and Natural History of Epilepsy-Dyskinesia SyndromesBoston Children's Hospital
- RECRUITINGNCT07202494Integrating Metabolism, Connectivity, and Mesoscale Imaging at Ultra-high Field to Decipher Mechanisms of Resilience and Neurodegeneration in Neurological Diseases and Healthy AgingAssistance Publique Hopitaux De Marseille
- RECRUITINGNCT05524493High-field MR Imaging in Migraine, Visual Snow and EpilepsyUniversity of Zurich
- RECRUITINGNANCT06847152Spatial Memory and Temporal Lobe EpilepsyCentre Hospitalier Metropole Savoie
- RECRUITINGNANCT06813612Effect of Cognitive Behavioral Play Intervention and EpilepsyIRCCS National Neurological Institute "C. Mondino" Foundation
- RECRUITINGNANCT06492720A Pilot Study to Evaluate the Efficacy and Safety of NaviFUS™ System Neuromodulating Treatment for Patients With Drug Resistant EpilepsyNaviFUS Corporation